Progressive failure of insulin-producing b-cells is the central event leading to diabetes, but the signaling networks controlling b-cell fate remain poorly understood. Here we show that SRp55, a splicing factor regulated by the diabetes susceptibility gene GLIS3, has a major role in maintaining the function and survival of human b-cells. RNA sequencing analysis revealed that SRp55 regulates the splicing of genes involved in cell survival and death, insulin secretion, and c-Jun N-terminal kinase (JNK) signaling. In particular, SRp55-mediated splicing changes modulate the function of the proapoptotic proteins BIM and BAX, JNK signaling, and endoplasmic reticulum stress, explaining why SRp55 depletion triggers b-cell apoptosis. Furthermore, SRp55 depletion inhibits b-cell mitochondrial function, explaining the observed decrease in insulin release. These data unveil a novel layer of regulation of human b-cell function and survival, namely alternative splicing modulated by key splicing regulators such as SRp55, that may cross talk with candidate genes for diabetes.
Diabetes is caused by loss and/or functional impairment of insulin-producing pancreatic b-cells. Type 1 diabetes (T1D) and type 2 diabetes (T2D) differ in their genetic background, associated environmental factors, and clinical history, but both forms of diabetes show loss of b-cell mass, which is near total in long-term T1D and in the range of 20-50% in T2D (1) (2) (3) . The mechanisms leading to this decrease in functional b-cell mass remain elusive, which may explain why intervention trials aiming to halt or revert b-cell loss in diabetes have consistently failed.
Genetic variations in the transcription factor GLIS3 are associated with susceptibility to both T1D and T2D (4, 5) . GLIS3 mutations also cause a neonatal diabetes syndrome characterized by neonatal diabetes, congenital hypothyroidism, and polycystic kidney (6) . Functional studies have shown that GLIS3 regulates b-cell differentiation and insulin transcription (7, 8) . We showed that GLIS3 is also required for adult b-cell survival, increasing basal apoptosis when depleted in rodent and human b-cells and sensitizing these cells to cytokine-and palmitate-induced apoptosis (9) . Increased b-cell apoptosis in Glis3-depleted b-cells in rats is associated with inhibition of the splicing factor SRp55 (also known as Srsf6), leading to a splicing shift in the proapoptotic protein Bim that favors the expression of the most prodeath splice variant Bim S (9) .
Alternative splicing (AS) is a key posttranscriptional mechanism in which different combinations of splice sites in the precursor mRNA are selected to generate structurally and functionally distinct mRNA and protein variants. Functionally related transcript populations are regulated by master splicing factors in coordinated "splicing networks" that modulate cell-, tissue-, or developmental-specific functions (10,11). Little is known of the role of AS in diabetes, but recent findings by our group indicate that neuron-enriched splicing factors play important roles in b-cell function and survival (12, 13) and that inflammatory and metabolic stresses induce different "AS signatures" in human b-cells (14, 15) .
The splicing factor SRp55 has been implicated in wound healing and oncogenesis, acting as an oncoprotein that promotes cell proliferation, cell survival, and hyperplasia in cancer (16, 17) . In this study, we analyzed the global role of SRp55 in b-cell function and survival using human pancreatic islets and the human insulin-producing EndoC-bH1 cell line. We found that SRp55 deficiency leads to increased b-cell apoptosis, impaired mitochondrial respiration, and defective insulin secretion. These findings indicate that SRp55 is a key downstream mediator of GLIS3 function, suggesting that splicing networks regulated by the cross talk between master splicing factors and candidate genes may contribute to b-cell dysfunction and death in diabetes.
RESEARCH DESIGN AND METHODS

Culture of Human Islets and EndoC-bH1 Cells
Human islets from donors without diabetes were isolated in Pisa, Italy, using collagenase digestion and density gradient purification. Islets were cultured at 6.1 mmol/L glucose as described previously (14) . Donor characteristics are described in Supplementary Table 1 . Human insulin-producing EndoC-bH1 cells were provided by Dr. R. Sharfmann (Institut Cochin, Université Paris Descartes, Paris, France); they were grown on plates coated with Matrigel and fibronectin (100 and 2 mg/mL, respectively) and cultured in DMEM as previously described (18) . In some experiments EndoCbH1 cells were exposed to the human cytokines interleukin1b (50 units/mL; R&D Systems, Abingdon, U.K.) and interferon-g (1,000 units/mL; Peprotech, London, U.K.) for 48 h, as described previously (14) .
Gene/Splice Variant Silencing and Overexpression
The small interfering RNAs (siRNA) targeting the human genes/splice variants used in this study are described in Supplementary Table 2 ; Allstars Negative Control siRNA (Qiagen, Venlo, Netherlands) was used as a negative control (siCTL). Transient transfection was performed using 30 nmol/L siRNA and Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). A pcDNA FLAG plasmid containing the human cDNA sequence of SRSF6 (SRp55), provided by Professor Hirokazu Hara (Gifu Pharmaceutical University, Gifu, Japan), was used to exogenously express SRp55 in EndoCbH1 cells.
Assessment of Cell Viability
Cell viability was determined using fluorescence microscopy after incubation with the DNA-binding dyes Hoechst 33342 and propidium iodide, as described previously (19) . In some experiments apoptosis was further confirmed by immunostaining for cleaved caspase-3.
RNA Sequencing
Total RNA was isolated from five independent preparations of EndoC-bH1 cells exposed to control (siCTL) or SRp55 (siSR#2) siRNA using the RNeasy Mini Kit (Qiagen, Venlo, the Netherlands). RNA sequencing was performed on an Illumina HiSEq 2000 Sequencing System as previously described (12, 20) . The raw data generated were deposited in Gene Expression Omnibus under submission number GSE98485.
RNA Sequencing Analysis
RNA sequencing reads were mapped to the human reference genome GRCh37/hg19 using TopHat 2 (14) and the Gencode annotation data set. Transcript abundance and differential expression were calculated using Flux Capacitor (21) . All genes and transcripts have been assigned a relative expression level as measured in reads per kilobase per million mapped reads (RPKM). A gene/isoform was considered to be expressed if it had a RPKM $0.5. Up-and downregulated genes were identified by computing the Fisher exact test and corrected by the Benjamini-Hochberg method, as previously described (14) . A minimum of 17% change (log twofold change of 60.23) in the expression level between SRp55 knockdown (KD) and control was considered to be "modified expression."
AS events were analyzed using rMATS (22) , which computes percentage splicing index (PSI) and the false discovery rate (FDR) for five different splicing events: skipped exons, mutually exclusive exons, retained introns, and 59 and 39 alternative splice sites. To identify significant changes, we used the cutoffs of 5% on DPSI and of 0.01% on FDR. Motif enrichment was analyzed in the vicinity of alternatively spliced exons using rMAPS (23) by comparing the spatial occurrence of two SRp55 motifs (17, 24) between cassette exons whose inclusion is affected by SRp55 KD and nonmodified exons showing an FDR $50%.
Functional annotation and pathway enrichment of genes presenting splicing and/or gene expression alterations were analyzed using the Database for Annotation, Visualization and Integrated Discovery and Ingenuity Pathway Analysis platforms (25) .
Validation of Splicing Changes by RT-PCR
Selected alternative splicing changes identified by RNA sequencing was validated by RT-PCR using exonic primers (Supplementary Table 3 ) encompassing the predicted splicing event. The primers were designed against flanking constitutive exons, allowing different splice variants to be distinguished based on fragment size. cDNA was amplified using MangoTaq DNA polymerase (Bioline), and PCR products were separated using the LabChip electrophoretic Agilent 2100 Bioanalyzer system and the DNA 1000 LabChip kit (Agilent Technologies, Wokingham, U.K.). The molarity of each PCR band corresponding to a specific splice variant was quantified using the 2100 Expert Software (Agilent Technologies, Diegem, Belgium), and used to calculate the ratio between inclusion and exclusion of the alternative event.
mRNA Extraction and Quantitative (Real-time) PCR Poly(A)+ mRNA was isolated using the Dynabeads mRNA DIRECT Kit (Invitrogen, Carlsbad, CA) and reverse transcribed as described previously (19) . Quantitative (realtime) PCR was performed using SYBR and concentrations were calculated as copies per microliter using a standard curve (26) . Gene expression was corrected for the reference gene b-actin. The primers used are listed in Supplementary  Table 3 .
Western Blotting and Immunofluorescence
For Western blotting, cells were washed with cold PBS and lysed in Laemmli buffer. Total proteins were resolved by 8-14% SDS-PAGE, transfected to a nitrocellulose membrane, and immunoblotted using the specific primary antibodies listed in Supplementary Table 4 . Densitometric values were corrected with the housekeeping protein a-tubulin as the loading control, after background subtraction. Double immunostaining was performed as previously described (9) .
Insulin Secretion
EndoC-bH1 cells were preincubated with culture medium containing 2.8 mmol/L glucose for 18 h. Cells were incubated in Krebs-Ringer buffer for 1 h and sequentially stimulated with 1 mmol/L glucose, 20 mmol/L glucose, or 20 mmol/L glucose and 10 mmol/L forskolin for 40 min, as described elsewhere (27) . Insulin release and insulin content were measured in cell-free supernatants and acid/ ethanol-extracted cell lysates, respectively, using a human insulin ELISA kit (Mercodia, Uppsala, Sweden). Results were normalized by total protein content.
Mitochondrial Respiration
Oxygen consumption rates of EndoC-bH1 cells were measured using the XFp Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA) as previously described (27) . After transfection, cells were preincubated in assay medium containing 1 mmol/L glucose at 37°C in air for 1 h. After that, respiration was measured following sequential injections of 20 mmol/L glucose, 5 mmol/L oligomycin, 4 mmol/L carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone (FCCP), and 1 mmol/L rotenone plus 1 mmol/L antimycin A. All data were normalized with total DNA content.
Statistical Analysis
Data are shown as mean 6 SD. Significant differences between experimental conditions were assessed by a paired Student t test or by ANOVA followed by Bonferroni correction, as indicated. P values ,0.05 were considered statistically significant.
RESULTS
SRp55 Regulates Human b-Cell Survival
Fluorescence microscopy indicated that SRp55 is highly expressed in pancreatic b-cells (Fig. 1A) . SRp55 mRNA expression is higher in human pancreatic islets and human insulin-producing EndoC-bH1 cells than in eight other human tissues (Fig. 1B) . To study the functional impact of SRp55 depletion on human b-cell survival, we silenced SRp55 using two specific siRNAs in human islets and EndoC-bH1 cells, reaching $50% inhibition at both the mRNA and protein levels (Fig. 1C , E, and F). SRp55 silencing significantly increased b-cell death in both dispersed human islets and in EndoC-bH1 cells ( Fig. 1D and G) .
The observed increase in cleaved caspase-3 expression in SRp55-depleted cells confirms that b-cell loss is mediated by apoptosis ( Fig. 1H and I) . Next, we analyzed whether SRp55 expression is affected by proinflammatory cytokines. Exposure of EndoC-bH1 cells to interleukin-1b and interferon-g significantly decreased SRp55 protein expression ( Supplementary Fig. 1A ). Overexpression of SRp55 in EndoC-bH1 cells ( Supplementary Fig. 1B ) protected these cells against cytokine-induced apoptosis ( Supplementary Fig.  1B ), suggesting that decreased SRp55 expression may contribute to b-cell death during islet inflammation.
Identification of SRp55-Regulated Splicing Events by RNA Sequencing
SRp55-regulated splicing events were detected by RNA sequencing of five independent EndoC-bH1 preparations under control conditions or after SRp55 KD, obtaining average coverage of 166 million reads. A total of 8,769 AS events were detected as modified after SRp55 KD ( Fig. 2A and Supplementary Table 5 ). The majority of modified AS events correspond to cassette exons (59%), followed by mutually exclusive exons (22%), alternative 59 splice site (9%), alternative 39 splice site (7%), and intron retention (3%) (Fig. 2B ).
Modified AS events affected 4,055 different genes (Supplementary Table 5 ). Functional enrichment analysis indicated that genes showing AS changes after SRp55 KD depletion are involved in diverse molecular and cellular functions, including cell cycle, DNA repair and replication, cell death and survival, and cellular function and maintenance (Fig. 2C ). Enriched pathways included several pathways involved in pancreatic b-cell function, dysfunction, and death ( Fig. 2D ), including genes related to T2D and insulin secretion, regulation of apoptosis, and c-Jun N-terminal kinase (JNK) signaling (Fig. 2D) .
SRp55 KD had a less marked impact on gene transcription when compared with RNA splicing (Supplementary Fig.  2A and B) . Nevertheless, SRp55 KD modified the expression of 2,981 genes, inducing predominantly gene upregulation ( Supplementary Fig. 2C and Supplementary Table 6 ). Of note, 28% of differentially expressed genes also presented changes on AS (Supplementary Fig. 2D ). Upregulated genes were enriched in pathways involved in the cell cycle, DNA repair and replication, and mitogen-activated protein kinase signaling, among others (Supplementary Table 6 ).
SRp55 Binding Motif Analysis
To study whether alternatively spliced genes are directly regulated by SRp55 and to identify spatial patterns of SRp55 binding, we performed an enrichment analysis of the SRp55 binding motifs. We compared the occurrence of SRp55 motifs between modified cassette exons and exons unaffected by SRp55 silencing. We analyzed the enrichment of two SRp55 motifs: a 6-mer motif identified by SELEX (24) , and a 9-mer motif identified by de novo discovery in modified exons after SRp55 overexpression in mouse skin (17) (Supplementary Fig. 3A ). Significant enrichment for both motifs in exonic regions was found in downregulated exons ( Supplementary Fig. 3C and D) . These results support the notion that SRp55, like most SR proteins (28) , acts as a splicing activator, promoting exon inclusion when bound to exonic splicing enhancers. In line with this, the majority of modified cassette exons (73%) displayed exon skipping after SRp55 depletion ( Supplementary Fig. 2B ), suggesting that a large proportion of modified splicing events are directly regulated by SRp55. Motif enrichment also indicated that upregulated events were not directly regulated by SRp55 and probably result from the impact of SRp55 on other splicing regulators, as we previously observed after Nova1 KD (12) .
Validation of Splicing Events
We next used independent EndoC-bH1 samples, different from the ones used for RNA sequencing, to confirm SRp55-regulated events. Representative genes of pathways regulating b-cell function and survival were selected for further Human islets were transfected with siCTL or specific siRNA against SRp55 (siSR#1 and siSR#2) for 48 h. SRp55 KD levels were assessed by qRT-PCR (C), and apoptosis was evaluated by Hoechst/propidium iodide (PI) staining (D). E-I: EndoC-bH1 cells were transfected with control or specific siRNA against SRp55 for 48 h. SRp55 KD levels were assessed by qRT-PCR (E) and by Western blotting (F). Apoptosis of EndoC-bH1 cells after SRp55 KD was evaluated by Hoechst/PI staining (G) and by cleaved caspase 3 immunofluorescence (H and I). Scale bars = 1 mm. Results are the mean 6 SEM of three to nine independent experiments. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. siCTL (paired t test). validation. We used RT-PCR followed by automated electrophoresis analysis based on primers that amplify isoforms presenting both inclusion and skipping of alternative fragments. We were able to validate 12 of 12 AS events tested (Fig. 3) , indicating good reliability of the data generated by RNA sequencing.
SRp55 Silencing Impairs Insulin Release and Leads to Mitochondrial Dysfunction
SRp55-depleted cells showed impaired insulin secretion at 20 mmol/L glucose and in the presence of glucose plus forskolin, but their insulin content did not change (Fig. 4A  and B) . Insulin release is regulated by ATP generation, and we next analyzed mitochondrial respiration by assessing the oxygen consumption rate using a Seahorse metabolic analyzer. SRp55-depleted EndoC-bH1 cells showed decreased mitochondrial respiration when compared with control cells, exhibiting lower basal respiration, impaired ATP production (response to oligomycin), and decreased maximal respiration (response to FCCP after oligomycin) (Fig. 4C-G) , suggesting that SRp55 silencing-induced mitochondrial dysfunction explains the observed defective glucose-induced insulin release.
Interestingly, RNA sequencing analysis indicated that several transcription factors that regulate the b-cell phenotype and affect insulin secretion were modified after SRp55 KD (Fig. 4H) . This includes upregulation of FOXO1 and NEUROD1, genes expressed in poorly differentiated endocrine cells (29) , and downregulation of PDX-1 and NKX6.1, key transcription factors for the maintenance of a differentiated b-cell phenotype (30, 31) .
SRp55 Contributes to b-Cell Apoptosis via Regulation of the Expression of Proapoptotic Splice Variants of BCL-2 Proteins
BCL-2 proteins are a family of apoptotic regulators that play a central role in b-cell survival (32) . RNA sequencing analysis indicated that SRp55 regulates splicing of the BCL-2 proteins BIM (BCL2L11), BAX, and BOK, and of related apoptotic proteins DIABLO and BCLAF1 (Figs. 2 and 3) . We previously showed that SRp55 KD in rat b-cells increases the expression of the most proapoptotic isoform Bim S (contributing to b-cell apoptosis) (9). Here we confirmed, at both the mRNA and protein levels, that SRp55 also regulates BIM splicing in human b-cells, increasing the proportion of BIM S over BIM L after SRp55 depletion ( Fig. 3B and Supplementary Fig. 4A and B ). An overall increase of BIM isoforms also occurred after SRp55 silencing (Supplementary Fig. 4A and C) . To assess the functional role of BIM in SRp55 KD-induced apoptosis, we performed a double KD of SRp55 and BIM ( Supplementary Fig. 4D-F) . BIM inhibition decreased EndoC-bH1 apoptosis to basal levels ( Supplementary Fig. 4F ), indicating that BIM plays a central role in regulating cell death in SRp55-depleted cells and suggesting that SRp55 depletion triggers the intrinsic or mitochondrial pathway of apoptosis.
SRp55 depletion also affected splicing of the apoptotic effector protein BAX, leading to increased intron 5 retention (Figs. 3A and 5A ). Unspliced intron 5 leads to the production of BAX b, a constitutively active isoform that may trigger cell death independent of upstream signaling (33) (Fig. 5B) . To test whether alteration of BAX splicing by SRp55 KD contributes to the observed increase in apoptosis, we designed a specific BAX b siRNA and performed single and double KD experiments in combination with SRp55 siRNA (Figs. 5C-F) . The upregulation of BAX b after SRp55 KD (Fig. 5E ) correlated with increased BAX translocation to the mitochondria (Fig. 5C ) and increased apoptosis (Fig. 5F ). Prevention of a BAX b increase by a specific siRNA in SRp55-depleted cells (Fig. 5E ) reduced BAX translocation to the mitochondria (Fig. 5C ) and protected EndoC-bH1 cells (Fig. 5F ) and human islets (Fig. 5G) against apoptosis, indicating a contributory role for BAX b in the observed phenotype. The JNK pathway has a proapoptotic role in pancreatic b-cells (34, 35) . RNA sequencing analysis indicated that SRp55 KD affects the splicing of several members of the JNK pathway (Figs. 2D, 3E-G, and 6A) . Moreover, several JNK signaling genes are upregulated after SRp55 silencing (Supplementary Table 6 ). To understand how these alterations affect JNK pathway activity, we first analyzed the phosphorylation state of the kinases MKK7 and JNK1, and the target transcription factor c-JUN. We observed that MKK7, JNK1, and c-JUN are hyperphosphorylated in SRp55-depeleted cells, whereas no changes in total protein levels were observed for MKK7 and JNK1 (Fig. 6B) . We hypothesized that splicing alterations in JNK-related signaling genes alter the pathway activity, contributing to increased b-cell death. To test this, we first performed a double KD of JNK1 and SRp55. Inhibition of JNK1 in both EndoC-bH1 cells and human islets protected them against SRp55 KD-induced apoptosis (Fig. 6C-F) . Next, we mimicked the impact of SRp55 depletion on the splicing of three JNK signaling kinases (MAP3K7, JNK1, and JNK2) using specific siRNAs against the SRp55-modified cassette exons in these genes. These siRNAs significantly increased the skipping of the cassette exons, recapitulating the effect of SRp55 KD (Figs. 6G-I) . It is interesting to note that increased exon skipping in all three JNK-related genes was associated with increased apoptosis (Fig. 6J ) and JNK hyperphosphorylation (Fig. 6K) in EndoC-bH1 cells. This supports the hypothesis that splicing alterations induced by SRp55 KD lead to hyperactivation of the JNK-regulated pathway and contribute to b-cell death.
SRp55 Depletion Induces Endoplasmic Reticulum Stress
RNA sequencing analysis showed that several genes of the endoplasmic reticulum (ER)-associated protein degradation pathway displayed AS alterations after SRp55 depletion and that some ER stress markers were upregulated at the gene expression level (Fig. 7A) . These findings suggest that reduced SRp55 levels affect ER function and may contribute to increased b-cell apoptosis. To test this hypothesis, we analyzed the expression of several ER stress markers at the protein and mRNA levels. Increased levels of phosphorylated and total IRE1a (Fig. 7B and C) and phospho-eIF2a ( Fig. 7B and E) were observed after SRp55 silencing. Moreover, induction of BIP (Fig. 7F) and XBP1 (Fig. 7G ) spliced mRNA was detected by quantitative PCR, indicating that SRp55 deficiency may directly or indirectly lead to ER stress. No significant changes, however, were observed for phosphorylated and total PERK and CHOP (Fig. 7D and H) . To determine whether ER stress indeed contributes to SRp55 KD-induced apoptosis, we performed double KD of IRE1a and SRp55 (Fig. 7I and J) . IRE1a silencing protected EndoC-bH1 cells against death induced by SRp55 (33) . Upon apoptotic signaling, BH3-only molecules such as BIM activate BAX a to promote its translocation and oligomerization to the mitochondrial outer membrane, leading to cytochrome c release and apoptosis activation. On the other hand, BAX b spontaneously targets, oligomerizes, and permeabilizes mitochondria, behaving as a constitutively active isoform. C-G: Double KD of SRp55 and BAX b in EndoC-bH1 cells (C-F) and in human islets (G). Cells were transfected with siCTL, siSR#2, siBaxb, or siSR#2 plus siBaxb for 48 h. C: Fluorescence microscopy analysis of BAX and the mitochondrial marker ATP synthase in EndoC-bH1 cells, showing that SRp55 KD leads to increased translocation of BAX to the mitochondria, a phenomenon prevented by BAX b silencing. Scale bar = 1 mm. mRNA expression of SRp55 (D) and BAX b (E) was measured by quantitative RT-PCR and normalized by the housekeeping gene b-actin. mRNA expression values were normalized by the highest value of each experiment, considered as 1. Proportion of apoptotic cells in EndoC-bH1 cells (F) and in dispersed human islets (G). Results are the mean 6 SEM of four or five independent experiments. *P , 0.05, **P , 0.01, and ***P , 0.001 vs. siCTL; ##P , 0.01 and ###P , 0.001 as indicated by bars (ANOVA followed by the Bonferroni post hoc test). deficiency (Fig. 7K) , demonstrating that defects in ER homeostasis and consequent ER stress promote apoptosis in SRp55-depleted cells.
DISCUSSION
These findings indicate that SRp55 drives a crucial splicing program to preserve human pancreatic b-cell survival and function. SRp55 is highly expressed in human pancreatic b-cells, and its depletion leads to b-cell apoptosis and impaired insulin secretion. SRp55 levels are downregulated by proinflammatory cytokines and may contribute to cytokineinduced b-cell apoptosis. These observations suggest that SRp55 acts as a master splicing regulator of b-cell survival under both basal and immune-induced stress conditions. In line with these observations, SRp55 regulates AS of multiple transcripts involved in cell death, JNK signaling, insulin secretion, and ER stress, providing a mechanistic link between the observed phenotype and SRp55 targets.
Our group previously showed that SRp55 is transcriptionally regulated by the transcription factor Glis3 (9). The GLIS3 locus is associated with T1D and T2D (4, 5) and with glucose metabolism traits in subjects without diabetes (36) , and its inactivation leads to a severe form of monogenic diabetes in humans (6, 37) . GLIS3 is also required for b-cell survival (9) , and defective Glis3 expression affects the unfolded protein response promoting b-cell fragility (38) . We observed in these experiments that decreased SRp55 expression recapitulates many of the pathological features induced by GLIS3 deficiency, for example, increased b-cell apoptosis, defective insulin release, and ER stress, suggesting that SRp55 may act as an important downstream mediator of GLIS3 function.
AS modulates the function of many BCL-2 proteins and other apoptotic regulators, producing variants that differ in their localization, posttranslation regulation, or proapoptotic activity (39, 40) . Our RNA sequencing analysis revealed that SRp55 regulates several genes involved in pancreatic b-cell apoptosis, including several BCL-2 proteins. It is important to note that SRp55 depletion affects the splicing of the apoptotic activator BAX, promoting the expression of the constitutively active isoform BAX b. The canonical isoform BAX a contains a COOH-terminal transmembrane domain tucked into the dimerization pocket that maintains BAX a in an autoinhibited monomeric conformation in the cytosol. After proapoptotic signaling, BH3-only activators such as BIM and PUMA induce a conformational change on BAX a, promoting its oligomerization, its translocation to the mitochondria, permeabilization of the outer membrane, and activation of apoptosis (41) . BAX b, on the other hand, retains intron 5, creating a distinct COOH-terminal domain that maintains it in a permanently activated conformation, leading to its spontaneous oligomerization and activation of apoptosis (33) . In addition, BAX b can also act as a BH3-only activator able to activate BAX a (33) . BAX a may also be activated by BIM S (42), shown here to be induced by SRp55 KD. The fact that independent KD of BAX b or BIM nearly completely prevents the increase in b-cell apoptosis observed after SRp55 KD suggests that both mechanisms are required to trigger the intrinsic pathway of apoptosis under these experimental conditions.
It is interesting that our data indicate that SRp55 regulates two other pathways potentially involved in b-cell death in cross talk with BCL-2 proteins, namely the JNK signaling cascade and ER stress. The JNK pathway has a pivotal role in integrating different stress signals and in promoting b-cell death (32, 43, 44) . JNK1 signaling stimulates the transcription and activity of proapoptotic BCL-2 proteins through activation of the transcription factor c-JUN and through direct phosphorylation (32) . Moreover, the JNK pathway is also activated by ER stress via the transmembrane protein IRE1a (45) . Different JNK splice variants may differ in their enzymatic activities, substrates, and activation/deactivation kinetics (46,47). For instance, a single splice change in MKK7 is able to increase the JNK pathway activity in T cells (48) . SRp55 depletion affects the splicing of several kinases of the JNK signaling cascade (as shown by the data presented here). These findings indicate that some of these changes modify the basal activity of the pathway, leading to JNK hyperactivation and contributing to b-cell apoptosis. JNK hyperactivation may also be secondary to the unfolded protein response via IRE1a signaling (45) . We observed that SRp55 silencing induces basal ER stress. The mechanisms by which SRp55 deficiency triggers ER stress remains to be clarified, but splicing alterations in ER-associated protein degradation genes suggest that ER function may be compromised through defective disposal of terminally misfolded proteins.
Reduced SRp55 expression also leads to impaired insulin release. Insulin exocytosis is tightly coupled to glucose metabolism, requiring mitochondrial ATP production to induce the closure of K ATP channels and the generation of Ca 2+ influx that ultimately triggers the release of insulin (49) . Our findings suggest that impaired insulin release induced by glucose is related to mitochondrial dysfunction. Furthermore, SRp55 silencing modifies the expression of genes and splice variants related to metabolic pathways, exocytosis, and calcium signaling, all of which potentially affect the regulation of insulin secretion. The findings described here are, however, correlative, and the precise mechanisms by which SRp55 depletion impairs b-cell function remain to be clarified.
In conclusion, the observations presented here indicate that SRp55 coordinates a splicing network of functionally interconnected genes in b-cells. These genes are required for b-cell survival and a functional phenotype. This suggests that alterations in SRp55-for instance, downstream of polymorphisms that decrease activity of the diabetes candidate gene GLIS3-may promote b-cell failure and loss in diabetes.
